2. Academic Validation
  3. Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

Oral strategies to target proprotein convertase subtilisin/kexin type 9 and lipoprotein(a): the new frontier of lipid lowering

  • Eur Heart J. 2023 Dec 21;44(48):5018-5020. doi: 10.1093/eurheartj/ehad682.
Giuseppe Danilo Norata 1,  Lale Tokgözoğlu 2
Affiliations

Affiliations

  • 1 Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
  • 2 Department of Cardiology, Hacettepe University School of Medicine, 06100 Ankara, Turkey.
PMID: 37947270 DOI: 10.1093/eurheartj/ehad682
Figures
Products